Individual differences in drug efficacy or toxicity can be influenced by genetic factors. We investigated whether polymorphisms of pharmacogenes that interfere with metabolism of drugs used in conditioning regimen and graft-versus-host disease (GvHD) prophylaxis could be associated with outcomes after HLA-identical hematopoietic stem cell transplantation (HSCT). Pharmacogenes and their polymorphisms were studied in 107 donors and patients with leukemia receiving HSCT. Candidate genes were: P450 cytochrome family (CYP2B6), glutathione-S-transferase family (GST), multidrug-resistance gene, methylenetetrahydrofolate reductase (MTHFR) and vitamin D receptor (VDR). The end points studied were oral mucositis (OM), hemorrhagic cystitis (HC), toxicity and venoocclusive disease of the liver (VOD), GvHD, transplantationrelated mortality (TRM) and survival. Multivariate analyses, using death as a competing event, were performed adjusting for clinical factors. Among other clinical and genetic factors, polymorphisms of CYP2B6 genes that interfere with cyclophosphamide metabolism were associated with OM (recipient CYP2B6*4; P ¼ 0.0067), HC (recipient CYP2B6*2; P ¼ 0.03) and VOD (donor CYP2B6*6; P ¼ 0.03). Recipient MTHFR polymorphisms (C677T) were associated with acute GvHD (P ¼ 0.03), and recipient VDR TaqI with TRM and overall survival (P ¼ 0.006 and P ¼ 0.04, respectively).Genetic factors that interfere with drug metabolisms are associated with treatment-related toxicities, GvHD and survival after HLA-identical HSCT in patients with leukemia and should be investigated prospectively.
Introduction
There are large differences in the way individuals respond to different treatments and medications. Although clinical characteristics as patients' age, sex, nature of the disease and organ functions are important causes for this variability, genetic factors as polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters and drug targets can also have a great influence on the efficacy and toxicity of a specific drug. 1 Huge advances in human genomics have identified many singlenucleotide polymorphisms, including those associated with substantial changes in the metabolism or effects of medications, and some are now being used to predict clinical outcomes. 2, 3 Allogeneic hematopoietic stem cell transplantation (HSCT) is an established but complex therapy for patients with hematological malignant and non-malignant diseases. Unfortunately, toxic complications, graft-versus-host disease (GvHD) and infections are associated with significant morbidity and mortality after HSCT. Genetic factors such as donor and recipient gene polymorphisms of host immune defense and pro-and antiinflammatory cytokines have been associated with the incidence of infections, GvHD and survival after HSCT. [4] [5] [6] [7] The better understanding of the pharmacology of drugs frequently used in transplants, including the study of genetic differences (polymorphisms) in the enzymes involved in their metabolic pathways, can also have a great potential in further improving HSCT outcomes. We hypothesized that recipient and donor pharmacogenes polymorphisms could be associated with toxicities and other outcomes after HLA-identical sibling HSCT in patients with leukemia. We selected pharmacogenes known to interfere with the metabolisms of the most frequent drugs used in this setting, that could be associated with toxicities: MTHFR (involved in the metabolism of methotrexate), P450 cytochrome CYP2B6 alleles (that can interfere with cyclophosphamide (CY) metabolism), 8 glutathione-S-transferases (involved in the metabolism of Busulfan) 9 or vitamin D receptor (VDR) gene, implicated in cyclosporine A (CsA) metabolism 10 and other immunologic functions.
Samples of 107 leukemia patients given HLA-identical HSCT and their respective donors were analyzed for the following candidate genes polymorphisms: P450 cytochrome family [CYP2B6*2(C64T), *3(C777A), *4(A785G), *5(C1459T), *6(G516T)] glutathione-S-transferases [GSTM1 (null), GSTT1 (null), GSTP1 (A313G)], Multidrug-resistance gene [MDR1 (C3435T)], Methylenetetrahydrofolate reductase [MTHFR (C677T, A1298C)], Vitamin D receptor [VDR (ApaI, TaqI and BsmI)]. The results were associated with mucositis, hemorrhagic cystitis (HC), liver toxicity, venoocclusive disease of the liver (VOD), GvHD, transplant-related mortality (TRM) and survival after HSCT. These series of patients and donors have been previously studied for host defence and inflammatory gene polymorphisms and results published. 6 
Materials and methods

Patient, donor and transplant characteristics
Inclusion criteria for patients in this study were: (1) non manipulated HLA-genoidentical sibling HSCT performed in Hô pital Saint Louis from January 1994 to August 1999, (2) patients with de novo acute or chronic leukemia, (3) donor and recipients DNA stored and (4) available clinical data. One hundred seven patients and their respective donors met these eligibility criteria. Patient-, donor-and transplant-related factors are listed in Table 1 .
Prophylaxis for acute GvHD consisted of the standard combination of CsA and methotrexate (MTX) and conditioning regimens varied according to the type of leukemia and status of the disease at transplant (Table 1 ). All patients were isolated in laminar airflow rooms. Bone marrow was harvested from both posterior iliac crests of the donors under general anesthesia. CD34 þ cell quantification was performed as previously described by fluorescence analysis. 11 
Gene polymorphism analysis
After informed consent, all donor and recipient genotypes were screened blindly and analyzed for the clinical outcome. Peripheral blood leukocytes from patients and donors were stored in liquid nitrogen and were used as a source of DNA. 12 Genes and their respective sites of polymorphisms, PCR conditions, primers sequences, size of the amplified fragments and the restriction enzyme used for digestion are indicated in Table 2 . Previously published PCR and restriction-digestion protocols were used to identify most of the polymorphisms. 13, 14, 19 The primers for CYP2B6*2 were designed by us, using the same enzyme (HaeII) described by Lang et al. 13 For GSTT1 and GSTM1, the product of the PCR was analyzed by electrophoresis on 1% agar and the presence or the absence of the amplified segment was recorded. This approach only distinguishes the null-allele homozygotes from the individuals who have one or more undeleted alleles.
End point definitions Toxicities. Oral Mucositis was classified as: absentFif there was no pain complaints and no impairment of oral intake; mildFmore than a half of daily intake per os and no necessity of parenteral morphine; moderateFmore than half of the daily intake per os and necessity of morphine; severeFnecessity of parenteral nutrition and morphine, and very severe was based on requirement for prophylactic intubation.
Hemorrhagic cystitis (HC) was defined retrospectively according to the criteria of Bedi (grade I, microscopic hematuria; grade 2, macroscopic hematuria; grade 3, macroscopic hematuria with clots; grade 4, macroscopic hematuria with clots and impaired renal function secondary to urinary tract obstruction). 20 Liver toxicity was defined by frequent measurements of total serum bilirubin (mmol/L), alanine aminotransferase (ALT, U/L) aspartate aminotransferase (AST, U/L), alkaline phosphatase (ALP, U/L) and g-glutamyl transferase (gGT, U/L). Median, maximum level and difference between highest and baseline levels were taken in consideration for each measurement.
Venocclusive disease (VOD) was diagnosed based on development of hepatomegaly, weight gain and jaundice as described earlier. 21 The severity of VOD was classified as mild, moderate and severe according to McDonald's criteria. 21 Other outcomes. Neutrophil recovery was defined as the first of 3 consecutive days of neutrophils more than 0.5 Â 10 9 /l during the first 42 days after transplant. Platelet recovery was defined as the first of 7 days of unsupported platelets more than 20 Â 10 9 /l during the first 180 days after transplant. Acute graft-versus-host disease (aGvHD) was diagnosed and graded according to published criteria. 22 All patients were considered evaluable for acute GvHD at day þ 1 after transplant. Occurrence of chronic GvHD was evaluated among patients who survived with sustained engraftment from day þ 100 after transplant. 23 Transplantation-related mortality (TRM) was calculated from transplantation to death related to transplant and not to relapse, until day 180. Overall survival was calculated from transplantation to death from any cause.
Statistical analysis
Univariable and multivariable proportional hazards regression models were used to identify independent risk factors of death and treatment-related mortality by means of log-rank tests and Cox proportional hazards models, respectively. The predictive effect of each of recipient and donor gene polymorphisms (Table 3) was assessed according to the frequency in the cohort studied. On account of the low frequency of recipient and donor CYP2B6*3 (C777A) variant alleles in the analyzed group, these polymorphisms were not included in the analysis. Other clinical-related variables studied were: recipient and donor Pharmacogenes polymorphisms and outcomes after HSCT V Rocha et al ages, recipient and donor genders, gender compatibility (female donor to a male recipient), recipient and donor CMV serology and match, ABO compatibility, diagnosis of chronic leukemia, diagnosis of acute leukemia, status of disease, use of a radiationbased conditioning, use of BU þ CY, nucleated cell and CD34 þ cell doses. For assessment of prognostic factors GvHD (grade II-IV or grades III-IV), chronic GvHD, hemorrhagic cystitis and venoocclusive disease, a similar methodology was used in a competing risks setting, death being treated as a competing event. Grades of outcomes were collapsed according to number of patients, data of literature and impact on final outcomes. These choices were performed prior to the analysis of association between gene polymorphisms and outcomes, and it was not done as ad-hoc analyses, which could introduce bias. Univariable and multivariable analyses were then performed using Gray's test 32 and the proportional subdistribution hazard regression model of Fine and Gray. 33 A stepwise backward procedure was used to construct a set of independent predictors of each end point. All predictors achieving a P-value below 0.10 were considered, and sequentially removed if the P-value in the multiple model was above 0.05. Additionally, interactions between selected variables were tested, and the modified Akaike model selection criterion 34 was examined to verify that the selected models had improved estimated prediction risk compared to models with other covariates. For end points, namely GvHD (acute II-IV and chronic), TRM and survival, that were analyzed earlier in a study published elsewhere, 6 the pharmacogenes polymorphisms were added to existing prognostic models accounting for clinical variables and host defense and inflammatory gene polymorphisms (Table 7) , to avoid over-fitting the data by reconstructing new models on the same observations, even if the patient's follow-up was updated. We thus preferred to evaluate the benefit of including pharmacogene polymorphisms to predict outcomes after HSCT.
Association of recipient pharmacogene polymorphisms with mucositis or liver toxicity was tested using Fisher's exact tests, as no precise dates were available for these events. However, both For each allele, the nucleotide and amino acid changes are indicated (when appropriate), together with the primer sequences, PCR conditions (35 cycles for all the amplification protocols), size of the fragment amplified and the restriction enzyme. For GSTM1 and GSTT1, only the presence or the absence (null allele) of the fragment was recorded.
a Alelle CYP2B6*6: G516T together with A785G.
Pharmacogenes polymorphisms and outcomes after HSCT V Rocha et al events were reported in the 21 days following graft and no censoring occurred during this period. Such analyses were therefore valid, and rough percentages were equivalent to cumulative incidence estimates, treating death as a competing event. Moreover, for mucositis, odds-ratios and 95% confidence intervals (95%CIs) were obtained by unifactorial and multiple logistic regression with backward stepwise model selection, as described for previous analyses. Abbreviations: ND, not done; wt, wild type. *The frequency of the following genes for CYP2B6*3 (C777A) (100% of recipient and donors CC).
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All tests were two-sided. The type I error rate was fixed at 0.05 for determination of factors associated with time to event outcomes. Considering the large number of non-independent tests performed to determine prognostic factors of liver toxicity, a more stringent type I error rate of 0.001 was chosen in these analyses. Statistical analyses were performed with SAS 8.1 (SAS Inc., Cary, NC, USA) and Splus2000 (MathSoft, Inc., Seattle) software packages.
Results
Frequency of donor and recipient gene polymorphisms and corresponding phenotypes
The results of donors and recipients gene polymorphisms, the frequency of wild type and variant genotype are listed in Table 3 . The frequencies that we obtained are similar to those reported in the literature for populations of European origin (Table 3) . Some drugs used in HSCT, possible associations of interest in this field and some examples of corresponding phenotypes are given in Table 3 .
Outcomes Table 4 outlines overall outcomes and Table 5 the association of candidate genes polymorphisms with those outcomes.
Oral mucositis
Oral mucositis was observed in 83 patients. According to the classification mentioned above it was mild in 29 (27%), moderate in 32 (30%), severe in 21 (20%) and very severe in one patient (1%). One patient presented mucositis, however, it was not graded because of missing clinical data. In univariate analysis, two polymorphisms were associated with a higher incidence of mucositis (more than mild grade): (1) recipient CYP2B6*4 (66% in AG or GG versus 39% in AA), (OR ¼ 3.03; 95%CI ¼ 1.37; 6.73; P ¼ 0.007) and (2) recipient CYP2B6*6 (41% for GG and 64% for GT or TT, OR ¼ 2.61; 95%CI ¼ 1.18; 5.78; P ¼ 0.02). In a logistic regression analysis considering age (children or adults), conditioning regimen (total body irradiation (TBI) or busulfan) and status of disease at transplant, only recipient CYP2B6*4 (AG or GG) was associated with higher occurrence of mucositis (Tables 5 and 6 ).
Hemorrhagic cystitis
Thirty-eight patients presented hemorrhagic cystitis (10 grade I, 15 grade II, 13 grade III and 1 grade IV). Cumulative incidence of HC at day 100 was 34.6% (95% CI 25.5; 43.6). In univariate analysis the following factors were associated with higher incidence of HC: adults (P ¼ 0.008), chronic leukemia (P ¼ 0.0002), conditioning regimen BU þ CY (P ¼ 0.0001) and recipient CYP2B6*2A (P ¼ 0.03). The incidence of HC was 31.5% in recipients CYP2B6*2A with CC genotype compared with 60.0% recipients CT or TT (Figure 1a) . In a multivariate analysis, higher incidence of HC was associated with diagnosis of chronic leukemia [Hazard ratio (HR) ¼ 4.69; 95% CI ¼ 1.85; 11.9, P ¼ 0.001] and recipient CYP2B6*2A (CT or TT) (HR ¼ 2.22; 95% CI ¼ 1.07; 4.63, P ¼ 0.03). (Tables 5 and 6 ).
Toxicity and venoocclusive disease of the liver
For the entire group, the median serum levels, the highest level and the difference between highest level and baseline levels of bilirubin, ALT, AST, ALP and gGT levels are listed in Table 4 . We have not found any association between these measurements with pharmacogene polymorphisms.
VOD was diagnosed in 15 patients (nine mild, four moderate and two severe). Cumulative incidence of VOD at day 100 was 14% (95% CI 7.4; 20.6). In univariate analysis the following factors were associated with higher incidence of VOD: donor and recipient GG genotype of CYP2B6*6 (P ¼ 0.022) (Figure 1b) , and absence of total body irradiation (P ¼ 0.034). In multivariate analysis, only recipient and donor CYP2B6*6 GG genotype was associated with higher incidence of VOD (HR ¼ 3.49; 95% CI ¼ 1.12; 10.88; P ¼ 0.03). (Tables 5 and 6 ).
Acute graft-versus-host disease
Acute GvHD of grade II or more occurred in 45 patients with a cumulative rate of 42% at day 100. In univariate analysis, among all studied polymorphisms of pharmacogenes only MTHFR C677T was associated with the incidence of grade II-IV GvHD. Cumulative incidence of acute GvHD II-IV was 66.7% in recipients TT homozygous, 47.2% in CT recipients and 31.1% in CC genotype recipients (Figure 2 ). Other factors increasing the risk of acute GvHD (II-IV) were: female donor to male recipient (P ¼ 0.04) and major ABO incompatibility (P ¼ 0.04). In a previously published study, we also analyzed Table 4 Overall results of outcomes analyzed Pharmacogenes polymorphisms and outcomes after HSCT V Rocha et al the impact of pro-and anti-inflammatory gene polymorphisms in the same population, a multivariate analysis showed, that female donor to male recipient and donor IL-1Ra genotype (absence of IL-1RN*2) were independent factors increasing the risk of acute GVHD 6 (Table 7) . Thus, we included MTHFR C677T in this model and we found that recipient MTHFR C677T (CT or TT) (P ¼ 0.03), donor IL1Ra (high production) (P ¼ 0.02) and female donor to male recipient (P ¼ 0.05) were factors retained in this model for the occurrence of grade II-IV GvHD (Tables 5 and 6 ).
Acute GvHD of grade III or IV developed in 18 (17%) patients with an estimated incidence of 17% at day 100. In a univariate analysis, there was a trend of increased risk of acute GVHD (III-IV) in a recipient MTHFR C677T CT or TT genotypes (Figure 3a) . In a multivariate analysis only recipient VDR taqI of T) was associated with increased risk incidence of acute GVHD (III-IV) (HR ¼ 2.61; 95 CI% ¼ 1.23; 5.56; P ¼ 0.01) (Figure 3b ).
Chronic graft-versus-host disease
Chronic GvHD developed in 51 of 95 patients at risk. At 2 years the cumulative incidence rate was 51.6% (41.4; 61.7). In univariate analysis we found that donor GSTP1 (A313G) genotype (GG or GA) was associated with higher incidence of chronic GvHD. It was 63% in patients receiving a bone marrow from a donor GG or GA compared with 40.8% in patients receiving a bone marrow from a donor AA (P ¼ 0.0087). In our previous study, we have found that chronic GvHD was associated with recipient IL-10 and recipient IL-1Ra (absence of IL-1RN*2) gene polymorphisms 6 (Table 7) . So we included these factors in the multivariate model and found that the following factors were associated with the risk of developing chronic GvHD: recipient's age (Po0.0001), recipient IL-10 (P ¼ 0.04), female donor to male recipient (P ¼ 0.04) and donor GG or GA genotype of GSTP1 (P ¼ 0.0030) ( Tables 5 and 6 ).
Early transplant-related mortality (180-day TRM)
Twenty-four patients died of transplant-related complications during the first 180 days after transplant. At day 180, cumulative incidence of non-leukemic death was 22%. The main causes of TRM were: GvHD (n ¼ 7, 29%), infections (n ¼ 9, 37.5%), interstitial pneumonitis (n ¼ 3, 12.5%), late graft failure and infections (n ¼ 2, 8.5%), multiorgan failure (n ¼ 2, 8.5%) and hemorrhage (n ¼ 1, 4%). In univariate analysis donor CYP2B6*4 genotype and recipient VDRtaqI genotype were associated with the incidence of TRM (Figure 4a) . In a multivariable analysis, including both the genetic factors in the previous multivariate analysis model 6 (Table 7) , we found that risk of early death was increased for patients with advanced status of disease (P ¼ 0.004), older patients (P ¼ 0.001), donor myeloperoxidase polymorphism (P ¼ 0.02), donor FC g receptor IIIb (FCgRIIIb) (P ¼ 0.01) and recipient VDRtaqI (P ¼ 0.006) ( Tables 5 and 6 ). (Figure 4b ) increased the risk of death (Tables 5 and 6 ).
Discussion
The field of pharmacogenetics focuses largely on genetic polymorphisms in drug metabolizing enzymes, drug transporters (such as P-glycoprotein) and drug targets (receptors) and the translation of inherited differences into drug effects. 1 Some of these polymorphisms have been associated with substantial changes in the metabolism or effects of medications. When translated to clinical studies, such technology has permitted to detect inter-individual variability in drug response or drug toxicity. However, there are numerous reasons why this approach is still controversial since drug treatment outcome represents a complex phenotype, which is encoded by numerous genes, and is affected by many environmental factors. 35 In allogeneic HSCT, events secondary to high doses of cytotoxic agents used in the conditioning regimens are responsible for a high incidence of morbidity and mortality in the early post transplant period. Gene polymorphisms that interfere with the metabolism of these drugs have been described. In our study, we have selected genes that were likely to interfere with metabolism of drugs frequently used in the conditioning regimens and GvHD prophylaxis. Moreover, we studied a well-characterized series of patients with leukemia receiving uniform myeloablative preparative regimens and systematically evaluated for toxic events and outcomes after HSCT.
We found that polymorphisms of the gene of the P450 cytochrome family that encodes for the enzyme CYP2B6 were associated with mucositis, hemorrhagic cystitis and VOD. Cyclophosphamide (CY), along with Busulfan and irradiation, is one of the most commonly used agents in preparative regimens for patients with leukemia. Cyclophosphamide is a pro-drug that is hydroxylated by hepatic enzymes, including CYP2B6, 8 to form the active metabolite 4-hydroxycyclophosphamide (4-OH-CY) and consequently the intracellular form aldocyclophosphamide and its products: phosphoramide mustard and acrolein. 36, 37 Phosphoramide mustard, the predominant anti-tumor CY metabolite, has a highly inter-patient variability and it has recently been associated with VOD, bilirubin elevation, non-relapse mortality and survival after HSCT. 37 Acrolein is known as the major cause of hemorrhagic ); kg, kilo; MPO, myeloperoxidase; P, P-value.
a, *A significant interaction between donor ILRa and recipient MTHFR was found (P ¼ 0.012) and statistical model selection favored a model with donor IL1Ra (absence of IL-1RN*2) to recipient MTHFR C677T (CT or TT) HR:3.47 (1.94;6.19); P ¼ 0.0002. However, this model has little clinical interpretation and may be due to peculiar sample characteristics.
Pharmacogenes polymorphisms and outcomes after HSCT V Rocha et al cystitis and may also play a role in VOD and pulmonary injury. 9 Studies have demonstrated that CYP2B6 is a major enzyme in the bioactivation of CY, 36 and its genetic polymorphisms could explain the high degree of inter-patient variation in the pharmacokinetic parameters of CY and its active 4-OH-CY. 8, 13 In fact, a strong functional impact of CYP2B6*6 (G516T) has been identified on CY 4-hydroxylation. 8 Carriers of the mutant allele have a decreased CYP2B6 protein level, but with an enhanced catalytic ability, which could lead to the higher formation of these toxic metabolites and consequently decrease the formation of toxic products. 8 We found that the incidence of VOD was higher when a donor to a recipient GG genotype CYP2B6*6 (wild type) was present, possibly due to the higher formation of these toxic metabolites. We have also found that polymorphisms of CYP2B6*2 and CYP2B6*4 were associated with mucositis and hemorrhagic cystitis, respectively. Both polymorphisms are not very well studied and more data on their influence on the CY metabolism are needed. Of course, due to the retrospective approach of our analysis and relative small number of events such as VOD, all these results should be confirmed in larger series of patients prospectively followed with CY metabolite pharmacokinetics.
Glutathione-S-transferases are a group of enzymes involved in the phase II detoxification of a wide range of xenobiotics and chemotherapeutic agents, including Busulfan, by catalysing the conjugation of reactive electrophiles to glutathione. 38 The GST enzyme family includes the cytosolic isoforms GST-a (GSTA), m (GSTM), p (GSTP), y (GSTT) and s (GSTS). GST-A1, -T1, -P1 and -M1 are polymorphic and altered polymorphic frequency of genes encoding these proteins has been suggested to be implicated in susceptibility to diseases and drug effects including resistance to chemotherapy (Table 3) . It has been previously described that a higher incidence of VOD in patients with B-thalassemia, carriers of GSTM1 null genotype. 39 However, in our study, we were not able to find any association of GSTP1, T1 or M1 polymorphisms with liver toxicity or VOD. Strikingly, we found that GSTP1 was associated with chronic GvHD. In a multivariate analysis, among other factors, donor GG or GA genotype were associated with higher incidence of chronic GVHD. GSTP1 enzyme is highly present in lymphocytes and has interactions with multidrug-resistance protein (MRP). Inhibition of MRP2-mediated efflux activity by cyclosporine A is completely reversed by GSTP1-1-associated resistance, a result indicating that GSTP1-1-mediated cytoprotection is absolutely dependent on MRP2 efflux activity. 40 Homozygous GSTP1 AA genotype is associated with significantly higher levels of GST activity measured in lymphocytes. 41 Moreover, recent investigations, have uncovered that members of GSTs and related proteins could express multifunctional activities including modulation of T lymphocyte function. 42 Further experimental and clinical studies should confirm and explore these results.
A very interesting finding of our study was the association of MTHFR C677T, involved in the metabolism of methotrexate (MTX), with acute GvHD (II-IV). MTX is a drug used to prevent GVHD in association with CsA and it has been associated with oral mucositis and hematological complications. 43 MTX, by affecting the intracellular folate pool, influences the activity of the enzyme methylenetetrahydrofolate reductase (MTHFR), one of the enzymes in the folate pathway, which impacts several crucial cellular processes and its deficiency can have widespread consequences. Heterozygous and homozygous MTHFR knockout mice have been developed, and have shown raised plasma homocysteine, reduced survival, delayed development, cerebellar abnormalities and abnormal lipid deposition in the proximal aorta. 44 More than a dozen polymorphisms have been described in the MTHFR gene. 45 Of these, C677T and A1298C polymorphisms have been associated with altered phenotypes and adverse drug events. The C677T polymorphism, first described in the mid-1990s, results in an alanine to valine Pharmacogenes polymorphisms and outcomes after HSCT V Rocha et al substitution in the codon at nucleotide 677 of the MTHFR gene. 18 It leads to a thermolabile variant of the MTHFR with decreased enzyme activity, and subsequent increased plasma homocysteine levels, which may be important in mediating the gastrointestinal toxicity from MTX. 46 The homozygous C677T variant (TT), with about 30% of wild type activity, is present in about 8-10% of the general population. Heterozygotes have about 60% activity and form approximately 40% of the population. 18 In patients undergoing HSCT, previous studies have shown the association of the recipient C677T variant genotypes (CT and TT) with: higher incidence of oral mucositis, Table 7 Multivariable analysis for outcomes after HLA identical HSCT for patients with leukemia in previously published study Pharmacogenes polymorphisms and outcomes after HSCT V Rocha et al slower platelets recovery, increased hepatic toxicity, increased treatment-related mortality and decreased overall survival. 43, 47, 48 Regarding GVHD, studies show different findings. Murphy et al. 49 found a decreased incidence of acute and chronic GVHD in 140 matched related transplants when donors have a variant CT or TT genotypes, and no association with the recipients C677T polymorphisms. Robien et al. 50 studied 304 patients receiving both related and unrelated HSCT and found a decreased risk of detectable acute GVHD when the recipients had a variant 677T allele, and could not find an association for the donor MTHFR genotypes. In a study with 72 patients receiving HSCT for matched sibling donors, Kim et al 47 could not find any association with incidence of GVHD and MTHFR C677T polymorphisms. In our study, we analyzed patients with leukemia receiving an HLA-identical sibling HSCT. This situation offers an opportunity to study differences in clinical manifestations of allo-reactivity in a setting where HLA differences are not an issue. We found that the occurrence and severity of acute GvHD was higher among homozygous (TT) or heterozygous patients (CT), compared with CC wild type.
In our previous analysis, studying the same patients, we found that donor IL1-Ra and female donor to male recipient were the most important factors for acute GVHD. 6 We introduced the MTHFR polymorphism into this model, and we found that together with these factors, recipient MTFHR (TT or CT genotypes) was also an important factor for the occurrence of acute GVHD (II-IV). There was also a trend of higher incidence of acute GvHD III-IV in recipient MTHFR (TT or CT genotypes).
How can we explain the association of MTHFR C677T with the occurrence of acute GVHD? Based on previous findings of Ulrich et al, 51 that recipient TT and CT genotypes were associated with higher toxicity (mucositis), we could speculate that mucosal barrier injury is a background for the establishment of acute GVHD. Another hypothesis is that efficacy of MTX in preventing GvHD in TT or CT genotype is decreased due to the decreased activity of the enzyme. More studies should be done, correlating MTHFR genotypes, levels of serum MTX, homocysteine and folate and the incidence of acute GVHD, to verify these hypotheses.
Another MTHFR polymorphism analyzed in our study was A1298C (Table 3 ). In HSCT, the 1298C variant allele in recipients has been associated with increased risk of acute GVHD and higher risk of relapse after transplant in patients with LMC. 50, 52 We did not find any impact of the association of both recipient C677T and A1298C polymorphisms in the MTHRF gene with the incidence of acute GVHD, only remaining is the association of C677T with this outcome (data not shown). However, we have not found any association of this polymorphism with outcomes after HSCT.
We have also studied polymorphisms of the Vitamin D receptor (VDR) gene that mediates the action of vitamin D3. Several common allelic variants have been identified in the VDR gene, between them RFLPs for BsmI, ApaI, EcoRV and TaqI sites and variations in a poly-A tract within the 3 0 untranslated region. 53, 54 A strong degree of linkage disequilibrium has been found among these alleles with description of five different more common haplotypes, however it can vary between different populations. 53, 54 It is proposed that these polymorphisms exert their effects through enhanced transcription of the VDR gene or through altered mRNA stability. 53 We studied the polymorphisms of this gene based on the possible association of CsA metabolism and the immunoregulatory activities of 1,25 dihydroxyvitamin D3. 10 The 1,25 dihydroxyvitamin D3 (hormone) is one of the major regulators of calcium metabolism, stimulating intestinal calcium absorption and increasing bone reabsorption. In the kidney, this hormone regulates transcription of the calbindin-D28K gene. In rat, CsA-mediated downregulation of renal calbindin-D28k mRNA and decreased VDR gene expression, suggesting an impairment of the vitamin D pathway by CsA. 10 However, it has to be determined if there is an impairment of CsA metabolism according to the VDR gene polymorphisms. Besides this possible interaction with CsA, studies have suggested some immunoregulatory effects of 1,25 dihydroxyvitamin D3 such as enhancing the development of Th2 cell-mediated responses. 55 In allogeneic HSCT, the use of a vitamin D analog, MC 1288, has been shown to prevent acute GvHD in a rat model. 56 Middleton et al. 57 in a study with 88 transplant recipients and 80 of their sibling donors, found that the ApaI allele when present in the patients' genotype was associated with severe acute GVHD. Analysis of donor polymorphisms found that survival was substantially lower in patients' receiving grafts from ApaI AA donors. However, this difference was seen only in patients receiving multi-agent GVHD prophylaxis, and not in those receiving CsA alone. In our study, the presence of a T allele in the VDR taqI was associated with increased incidence of GvHD (III-IV), higher TRM and lower survival after HSCT. Our findings are in agreement with those reported by Middleton et al., 57 as B, A and t alleles are frequently associated in common haplotypes. In our study, there is no association of the three mutations and survival, however survival seemed rather linked to recipient VDR taqI and not to others (data not shown). ' Polymorphism at the taqI site has also been associated with localized early-onset periodontal disease 30 and susceptibility to leprous and tubercular subtypes of leprosy.
31 VDR (t) facilitate strong Th1-cell mediated immune response (demonstrated against M. tuberculosis and chronic hepatitis B infection), whereas VDR (T) possibly favor a Th2-cell lineage for newlyactivated CD4 þ cells. 58 One could also argue that the association of VDR gene polymorphism with acute GvHD or TRM could be explained by a higher incidence of infectious disease after transplant; however, we have not found any association of this polymorphism with the time to the first severe bacterial, viral or fungal infection during the first 180 days after TRM (data not shown).
Explanations for the association of VDR gene polymorphisms with GvHD and survival are speculative and these results should be confirmed in a larger series of patients. Despite the possible role in CsA metabolism, it seems based on Middleton et al. 57 and our results, that the VDR gene polymorphism may be involved in the immunological mechanisms associated with allogeneic HSCT which should be further explored. 55, 59 In conclusion, we found in this retrospective analysis, that polymorphisms of genes that interfere with drug metabolism used in preparative regimens for HSCT and GvHD prophylaxis are associated with toxicities, GVHD and survival. However, positive results in a small number of patients at risk could lead to false-positive results; therefore our findings should be confirmed in a larger series of patients. The accumulation of the knowledge in the field of pharmacogenomics will allow us to understand mechanisms of drugs effects and toxicities, to develop new therapeutic options and to individualize specific treatments, thus improving the final outcome of allogeneic HSCT.
